<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">healthcare</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение. Healthcare</journal-title><trans-title-group xml:lang="en"><trans-title>Healthcare</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1027-7218</issn><publisher><publisher-name>Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economics</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">healthcare-13</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group></article-categories><title-group><article-title>Т-клеточные механизмы иммунитета при COVID-19: изменения в костном мозге, тимусе, субпопуляциях лимфоцитов, оценка функции</article-title><trans-title-group xml:lang="en"><trans-title>T-cell mechnisms of immunity during COVID-19: changes in the bone marrow, thymus, lymphocyte subpopulations, assessment of function</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Титов</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Titov</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Титов Леонид Петрович— академик НАН Беларуси, д. м. н., профессор, главный научный сотрудник лаборатории клинической и экспериментальной микробиологии</p><p>Ул. Филимонова, 23, 220114, г. Минск</p><p>Сл. тел. +375 17 237-69-98.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трусевич</surname><given-names>М. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Trusevich</surname><given-names>M. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минск</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>РНПЦ эпидемиологии и микробиологии</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>22</day><month>09</month><year>2025</year></pub-date><volume>0</volume><issue>5</issue><fpage>29</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Титов Л.П., Трусевич М.О., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Титов Л.П., Трусевич М.О.</copyright-holder><copyright-holder xml:lang="en">Titov L.P., Trusevich M.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://healthcare.ejournal.by/jour/article/view/13">https://healthcare.ejournal.by/jour/article/view/13</self-uri><abstract><p>Представлен обзор научной литературы последних лет по проблеме SARS-CoV-2-инфекции: генетической изменчивости возбудителя, органах и клетках иммунной системы, оценке функции и способах коррекции. Проблема SARS-CoV-2-инфекции, возникшей в конце 2019 г. в Китае (г. Ухань) и развившейся в пандемию, представляет актуальную проблему и в 2024 г. Важно понять не только механизмы заражения и развития болезни, но и разработать эффективные меры и препараты для профилактики. Для этого необходим геномный мониторинг возбудителя для оценки мутационных изменений, которые помогают уклониться от Т-клеточного иммунного ответа. Молекулярно-генетические механизмы данного явления полностью не раскрыты. Вирусы реализуют стратегии уклонения от факторов иммунного ответа рядом способов: а) экранированием поверхностных антигенов путем добавления молекул сложных гликанов; б) секрецией усеченных вирусных гликопротеинов, имеющих общие с фрагментами вирусного шиповидного S-белка эпитопы; в) блокадой системы комплемента. Хотя основной мишенью вируса является иммунная система (костный мозг, тимус, другие лимфоидные образования и субпопуляции клеток), вирус атакует практически все органы и системы организма (легкие, сосуды сердца, головного мозга, почек, поджелудочной железы, половых желез). Обсуждается разнообразие субпопуляций Т-лимфоцитов, включая эффекторные Т-клетки, молекулярное распознавание антигенов, поражение и восстановление функции тимуса, оценки Т-клеточного специфического иммунитета. Рассматриваются сложности в оценке эффективности протективного специфического Т-клеточного иммунного ответа.</p></abstract><trans-abstract xml:lang="en"><p>The purpose of this study is to review the scientific literature of recent years on the problem of SARS-CoV-2 infection — genetic variability of the pathogen, organs and cells of the immune system, assessment of function and methods of correction. The problem of SARS-CoV-2 infection, which arose at the end of 2019 in China(Wuhan) and developed into a pandemic, is a pressing problem in 2024. It is important to understand not only the mechanisms of infection and development of the disease, but also to develop effective measures and drugs for prevention. This requires genomic monitoring of the pathogen to assess mutational changes that help evade the T-cell immune response. The molecular-genetic mechanisms of this phenomenon are not fully disclosed. Viruses implement strategies to evade immune factors in a number of ways: a) by shielding surface antigens by adding molecules of complex glycans: b) secretion of fruncated viral glicoproteins that have common epitopes with fragments of the viral spikeS protein; c) blockade of the complement system. Although the main target of the virus is the immune system(bone marrow,thymus, other lymphoid formation, subpopulation of cells), the virus attacks almost all organs and systems of the body(lungs, blood vessels, of the heart, brain, kidneys, pancreas, gonads). Discusses of the diversity of T-lymphocytes subsets, including effector T-cells. Molecular recognition of antigens, thymic injury/ recovery and assessment of T-cell-specific immunity. The difficulties in assessing the effectiveness of a protective specific T-cell immune response are considered.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>костный мозг</kwd><kwd>тимус</kwd><kwd>Т-клетки</kwd><kwd>протективный иммунитет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>bone marrow</kwd><kwd>thymus</kwd><kwd>T-cells</kwd><kwd>protective immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Титов Л. П., Спринджук М. В. COVID-19: характеристика возбудителя, механизмы естественного и адаптивного иммунного ответа, генетическое разнообразие и распространенность. Весц1 НАНБ. Медыцынская серыя. 2021; 18 (4): 497—512.</mixed-citation><mixed-citation xml:lang="en">Titov L. P, Sprindzhuk M. V. COVID-19: characteristics of the pathogen, mechanisms of natural and adaptive immune response, genetic diversity and prevalence. Vestsi NANB. Medytsynskaya seryya. 2021; 18 (4): 497—512. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">COVID-Coronavirus Statistics. 2023. Available at: https://www.worldometers.Info.</mixed-citation><mixed-citation xml:lang="en">COVID-Coronavirus Statistics. 2023. Available at: https:/ /www.worldometers.Info.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Belarus COVID — Coronavirus Statistics. 2023. Available at: https://www.worldometers.info.</mixed-citation><mixed-citation xml:lang="en">Belarus COVID — Coronavirus Statistics. 2023. Available at: https://www.worldometers.info.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Markov P. V., Ghafari M., Beer M. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023; 21: 361—79.</mixed-citation><mixed-citation xml:lang="en">Markov P. V., Ghafari M., Beer M. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023; 21: 361—79.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Young A. T cells in SARS-CoV-2 infection and vaccination. Ther. Adv. Vaccines Immunother. 2022; 10:25151355221115011.</mixed-citation><mixed-citation xml:lang="en">Young A. T cells in SARS-CoV-2 infection and vaccination. Ther. Adv. Vaccines Immunother. 2022; 10:25151355221115011.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yang W. T, Huang W. H., Liao T L. etal. SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. Infect. Drug Resist. 2022; 15: 373—85.</mixed-citation><mixed-citation xml:lang="en">Yang W. T., Huang W. H., Liao T. L. et al. SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. Infect. Drug Resist. 2022; 15: 373—85.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mittal A., Khattri A., Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. PLoSPathog. 2022; 18(2): e1010260.</mixed-citation><mixed-citation xml:lang="en">Mittal A., Khattri A., Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. PLoSPathog. 2022; 18(2): e1010260.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Arora P, CossmannA., Schulz S.R. et al. Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. Lancet Infect. Dis. 2023; 23 (2): 14 7—8.</mixed-citation><mixed-citation xml:lang="en">Arora P, CossmannA., Schulz S. R. etal. Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. Lancet Infect. Dis. 2023; 23 (2): 14 7—8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y., Yang C., Xu X. F et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta.Pharmacol. Sin. 2020; 41 (9): 1141—9.</mixed-citation><mixed-citation xml:lang="en">Huang Y., Yang C., Xu X. F et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta.Pharmacol. Sin. 2020; 41 (9): 1141—9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fleri W., Paul S., Dhanda S. K. et al.The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design. Front. Immunol. 2017; 8: 278.</mixed-citation><mixed-citation xml:lang="en">Fleri W., Paul S., Dhanda S. K. et al. The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design. Front. Immunol. 2017; 8: 278.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Reche P A., Zhang H., Glutting J. P, Reinherz E. L. EPIMHC: a curated database of MHC-binding peptides for customized computational vaccinology. Bioinformatics. 2005; 21 (9): 2140—1.</mixed-citation><mixed-citation xml:lang="en">Reche P A., Zhang H., Glutting J. P, Reinherz E. L. EPIMHC: a curated database of MHC-binding peptides for customized computational vaccinology. Bioinformatics. 2005; 21 (9): 2140—1.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Титов Л. П. Медицинская геномика: организация генома, регуляция экспрессии генов, вариабельность. Вести НАНБ. Медицинская серия. 2015; 3: 97—113.</mixed-citation><mixed-citation xml:lang="en">Titov L. Р. Medical genomics: genome organization, regulation of gene expression, variability. Vesti NANB. Meditsinskaya seriya. 2015; 3: 97—113. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kopanska M., Barnas E., Blajda J. et al. Effects of SARS-CoV-2 Inflammation on Selected Organ Systems of the Human Body Int. J. Mol. Sci. 2022; 23 (8): 4178.</mixed-citation><mixed-citation xml:lang="en">Kopanska M., Barnas E., Blajda J. et al. Effects of SARS-CoV-2 Inflammation on Selected Organ Systems of the Human Body Int. J. Mol. Sci. 2022; 23 (8): 4178.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">KumarB. V., Connors T J., FarberD. L. Human T cell development, localization, and function throughout life. Immunity. 2018; 48(2): 202—13.</mixed-citation><mixed-citation xml:lang="en">KumarB. V., Connors T J., FarberD. L. Human T cell development, localization, and function throughout life. Immunity 2018; 48(2): 202—13.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sovani V. Normal bone marrow, its structure and function. Histopathology. 2021; 27 (9): 349—56.</mixed-citation><mixed-citation xml:lang="en">Sovani V. Normal bone marrow, its structure and function. Histopathology 2021; 27 (9): 349—56.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Elahi S. Hematopoietic responses to SARS-CoV-2 infection. CellMol. LifeSci. 2022; 79 (3): 187.</mixed-citation><mixed-citation xml:lang="en">Elahi S. Hematopoietic responses to SARS-CoV-2 infection. CellMol. LifeSci. 2022; 79 (3): 187.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Бобрукевич Д., Антоневич Н., Ганчаров А. и др. Характеристика состояния системы иммунитета у пациентов с пневмонией, ассоциированной с COVID-19. Наука и инновации. 2022; 2: 24—35.</mixed-citation><mixed-citation xml:lang="en">Bobrukevich D., Antonevich N., Goncharov A. i dr. Characteristics of the state of the immune system in patients with pneumonia associated with COVID-19. Naukaiinnovatsii. 2022; 2: 24—35. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Moss Р. The Т cell immune response against SARS-CoV-2. Nat. Immunol. 2022; 23 (2): 186—93.</mixed-citation><mixed-citation xml:lang="en">Moss Р. The T cell immune response against SARS-CoV-2. Nat. Immunol. 2022; 23 (2): 186—93.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">ШевыревД. В., Терещенко В. П., Козлов В. А. Гомеостатическая пролиферация: от нормы к патологии. Российский иммунологический журнал. 2018; 21 (2): 91—105.</mixed-citation><mixed-citation xml:lang="en">Shevyrev D. V., Tereshchenko V. Р., Kozlov V. A. Homeostatic proliferation: from normal to pathological. Rossiyskiy immunologicheskiy zhurnal. 2018; 21 (2): 91— 105. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson J. J., Susser Е., Arbeev К. G. etal. Telomerelength dependent T-cell clonal expansion: A model linking ageing to COVID-19 T-cell lymphopenia and mortality. EBio Medicine. 2022; 78: 103978.</mixed-citation><mixed-citation xml:lang="en">Anderson J. J., Susser E., Arbeev K. G. etal. Telomerelength dependent T-cell clonal expansion: A model linking ageing to COVID-19 T-cell lymphopenia and mortality. EBio Medicine. 2022; 78: 103978.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Титов Л. П. Иммунология: терминологический словарь. Москва. МИА; 2008. 541 с.</mixed-citation><mixed-citation xml:lang="en">Titov L. Р. Immunology: terminological dictionary. M.: MIA; 2008. 541 s. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ластовка И. Н., Улезко Е. А., Матвеев В. А. Оценка величины вилочковой железы у новорожденных по данным ультразвукового исследования. Проблемы здоровья и экологии. 2007; 4 (14): 38—42.</mixed-citation><mixed-citation xml:lang="en">Lastovka I. N., Ulezko E. A., Matveev V. A. Assessment of the size of the thymus gland in newborns according to ultrasound data. Problemy zdorov’ya i ekologii. 2007; 4 (14): 38—42. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Титов Л. П., Кирильчик Е. Ю., Канашкова Т. А. Особенности строения, развития и функционирования иммунной системы детского организма. Медицинские новости. 2009; 5: 7—16.</mixed-citation><mixed-citation xml:lang="en">Titov L. P, Kiril’chik E. Yu., Kanashkova T A. Features of the structure, development and functioning of the immune system of the child’s body Meditsinskie novosti. 2009; 5: 7— 16. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lins M. Р, Smaniotto S. Potential impact of SARS-CoV-2 infection on the thymus. Can. J. Microbiol. 2021; 67 (1): 23—8.</mixed-citation><mixed-citation xml:lang="en">Lins M. P, Smaniotto S. Potential impact of SARS-CoV-2 infection on the thymus. Can. J. Microbiol. 2021; 67 (1): 23—8.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">As-Suhami E. A. A., Aljafari M. A., Alkhulaifi F M. et al. Thymus Gland: A Double Edge Sword for Coronaviruses. Vaccines (Basel). 2021; 9 (10): 1119.</mixed-citation><mixed-citation xml:lang="en">As-Suhami E. A. A., Aljafari M. A., Alkhulaifi F M. et. al. Thymus Gland: A Double Edge Sword for Coronaviruses. Vaccines (Basel). 2021; 9 (10): 1119.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Weinreich M. A., Hogquist К. A. Thymic emigration: when and how T cells leave home. J. Immunol. 2008; 181 (4): 2265—70.</mixed-citation><mixed-citation xml:lang="en">Weinreich M. A., Hogquist K. A. Thymic emigration: when and how T cells leave home. J. Immunol. 2008; 181 (4): 2265—70.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kong F, Chen C. H., Cooper M. D. Thymic function can be accurately monitored by the level of recent T cell emigrants in the circulation. Immunity. 1998; 8 (1): 97—104.</mixed-citation><mixed-citation xml:lang="en">Kong F, Chen C. H., Cooper M. D. Thymic function can be accurately monitored by the level of recent T cell emigrants in the circulation. Immunity. 1998; 8 (1): 97—104.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rechman S., Majeed T, Ansari M. A. et al. Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response. Saudi J. Biol. Sci. 2020; 27 (10): 2567—73.</mixed-citation><mixed-citation xml:lang="en">Rechman S., Majeed T, Ansari M. A. et al. Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response. Saudi J. Biol. Sci. 2020; 27 (10): 2567—73.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Rosati E., Dawds C. M., Liaskou E. et al.Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 2017; 17 (1): 61.</mixed-citation><mixed-citation xml:lang="en">Rosati E., Dawds C. M., Liaskou E. et al. Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 2017; 17 (1): 61.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kellogg C., Equils O. The role of the thymus in COVID-19 disease severity: implications for antibody treatment and immunization. Hum. Vaccin. Immunother. 2021; 17 (3): 638—43.</mixed-citation><mixed-citation xml:lang="en">Kellogg C., Equils O. The role of the thymus in COVID-19 disease severity: implications for antibody treatment and immunization. Hum. Vaccin. Immunother. 2021; 17 (3): 638—43.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Yap J. P, Wirasinha R. C., Chan A. et al. Indirect presentation in the thymus limits naive and regulatory T-cell differentiation by promoting deletion of self-reactive thymocytes. Immunology 2018; 154 (3): 522—32.</mixed-citation><mixed-citation xml:lang="en">Yap J. P, Wirasinha R. C., Chan A. et al.Indirect presentation in the thymus limits naive and regulatory T-cell differentiation by promoting deletion of self-reactive thymocytes. Immunology 2018; 154 (3): 522—32.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Berkan O., Kiziloglu I., Keles E. et al. Does the Thymus Index Predict COVID-19 Severity? J. Comput. Assist. Tomogr. 2023; 47 (2): 236—43.</mixed-citation><mixed-citation xml:lang="en">Berkan O., Kiziloglu I., Keles E. et al. Does the Thymus Index Predict COVID-19 Severity? J. Comput. Assist. Tomogr. 2023; 47 (2): 236—43.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Markert M. L., Devlin B. H., McCarthy E. A. Thymus transplantation. Clin. Immunol. 2010; 135 (2): 236—46.</mixed-citation><mixed-citation xml:lang="en">Markert M. L., Devlin B. H., McCarthy E. A. Thymus transplantation. Clin. Immunol. 2010; 135 (2): 236—46.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Consolini R., Legitimo A., Calleri A., Milani M. Distribution of age-related thymulintitres in normal subjects through the course of life. Clin. Exp. Immunol. 2000; 121 (3): 444—7.</mixed-citation><mixed-citation xml:lang="en">Consolini R., Legitimo A., Calleri A., Milani M. Distribution of age-related thymulintitres in normal subjects through the course of life. Clin. Exp. Immunol. 2000; 121 (3): 444—7.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Brabre I. den, Mugwagwa T., Vrisekoop N. et al. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 2012; 36 (2): 288—97.</mixed-citation><mixed-citation xml:lang="en">Brabre I. den, Mugwagwa T., Vrisekoop N. et al. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 2012; 36 (2): 288—97.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Maruyama S. The Functional Assessment of T cells. Methods Mol. Biol. 2018; 1868: 177—99.</mixed-citation><mixed-citation xml:lang="en">Maruyama S. The Functional Assessment of T cells. Methods Mol. Biol. 2018; 1868: 177—99.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Q., Iketani S., Liu Z. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023; 186 (2): 279—86.</mixed-citation><mixed-citation xml:lang="en">Wang Q., Iketani S., Liu Z. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023; 186 (2): 279—86.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Nowill A. E., Caruso M., de Campos-Lima P.O. T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets. Front. Immunol. 2023; 14: 1133225.</mixed-citation><mixed-citation xml:lang="en">NowillA. E., Caruso M., de Campos-Lima P O. T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets. Front. Immunol. 2023; 14: 1133225.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Santegoets S., Welters M. J. P, van der Burg S. H. Detection and functional assessment of regulatory T-cells in clinical samples. J. Immunotherapy of Cancer. 2014; 2 (3): 154.</mixed-citation><mixed-citation xml:lang="en">Santegoets S., Welters M. J. P, van der Burg S. H. Detection and functional assessment of regulatory T-cells in clinical samples. J. Immunotherapy of Cancer. 2014; 2 (3): 154.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Кудрявцев И. В., Головкин А. С., Тотолян А. А. Т-хелперы и их клетки-мишени при COVID-19. Инфекция и иммунитет. 2022; 12 (3): 409—26.</mixed-citation><mixed-citation xml:lang="en">Kudryavtsev I. V., Golovkin A. S., Totolyan A. A. T helper cells and their target cells in COVID-19. Infektsiyaiimmunitet. 2022; 12 (3): 409—426. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Bekbossynova M., Akhmaltdinova L., Dossybaeva К. et al. Central and effector memory T cells in peripheral blood of patients with interstitial pneumonia: preliminary clues from a COVID-19 study. Respir Res. 2022; 23 (1): 278.</mixed-citation><mixed-citation xml:lang="en">Bekbossynova M., Akhmaltdinova L., Dossybaeva K. et al. Central and effector memory T cells in peripheral blood of patients with interstitial pneumonia: preliminary clues from a COVID-19 study. Respir Res. 2022; 23 (1): 278.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Adamo S., MichlerJ., Zurbuchen Y etal. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection. Nature. 2022; 602 (7895): 148—55.</mixed-citation><mixed-citation xml:lang="en">Adamo S., MichlerJ., Zurbuchen Y. etal. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection. Nature. 2022; 602 (7895): 148—55.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Tian Y., Babor M., Lane J. et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat. Commun. 2017; 8 (1): 1473.</mixed-citation><mixed-citation xml:lang="en">Tian Y., Babor M., Lane J. et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat. Commun. 2017; 8 (1): 1473.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Tavukcuoglu E., Horzum U., CagkanInkaya A. et al. Functional responsiveness of memory T cells from COVID-19 patients. Cell Immunol. 2021; 365: 104363.</mixed-citation><mixed-citation xml:lang="en">Tavukcuoglu E., Horzum U., CagkanInkaya A. et al. Functional responsiveness of memory T cells from COVID-19 patients. Cell Immunol. 2021; 365: 104363.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z., Yang X., Zhong J. et al. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nat Commun. 2021; 12 (1): 1724.</mixed-citation><mixed-citation xml:lang="en">Wang Z., Yang X., Zhong J. et al. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nat Commun. 2021; 12 (1): 1724.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Kalpaskci Y., Hacibekiroglu T., Trak G. et al. Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4+CD8+ double positive T lymphocytes as a new marker. Rev. Assoc. Med. Bras. (1992). 2020; 66 (12): 1666—72.</mixed-citation><mixed-citation xml:lang="en">Kalpaskci Y., Hacibekiroglu T., Trak G. et al. Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4+CD8+ double positive T lymphocytes as a new marker. Rev. Assoc. Med. Bras. (1992). 2020; 66 (12): 1666—72.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Dhawan M., Rabaan A. A., Al Fawarch M. M. et al. Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines (Basel). 2023; 11(1): 101.</mixed-citation><mixed-citation xml:lang="en">Dhawan M., Rabaan A. A., Al Fawarch M. M. et al. Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines (Basel). 2023; 11(1): 101.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Lafon E., Diem G., Wilting C. H. et al. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. Front. Immunol. 2021; 12: 684014.</mixed-citation><mixed-citation xml:lang="en">Lafon E., Diem G., Wilting C. H. et al. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. Front. Immunol. 2021; 12: 684014.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">BertolettiA., Le BertN., TanA.T SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity. 2022; 55 (10): 1764—78.</mixed-citation><mixed-citation xml:lang="en">BertolettiA., Le BertN., Tan A. T SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity. 2022; 55 (10): 1764—78.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J. K. H., Lam G. K. L., Shin T et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and metaanalysis. Expert. Rev. Vaccines. 2018; 17 (5): 435—43.</mixed-citation><mixed-citation xml:lang="en">Lee J. K. H., Lam G. K. L., Shin T et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and metaanalysis. Expert. Rev. Vaccines. 2018; 17 (5): 435—43.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Duah M., Li L., Shen J. et al. Thymus Degeneration and Regeneration. Front. Immunol. 2021; 12: 706244.</mixed-citation><mixed-citation xml:lang="en">Duah M., Li L., Shen J. et al. Thymus Degeneration and Regeneration. Front. Immunol. 2021; 12: 706244.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Apasov S., Chen J. F, Smith P, Sitkovsky M. A(2A) receptor dependent and A(2A) receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood. 2000; 95 (12): 3859—67.</mixed-citation><mixed-citation xml:lang="en">Apasov S., Chen J. F, Smith P., Sitkovsky M. A(2A) receptor dependent and A(2A) receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood. 2000; 95 (12): 3859—67.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Shohat B., Joshua H. Suppressor, helper and immunoregulatory T cells in normal human blood as defined by theophylline sensitivity Thymus. 1982; 4 (6): 323—34.</mixed-citation><mixed-citation xml:lang="en">Shohat B., Joshua H. Suppressor, helper and immunoregulatory T cells in normal human blood as defined by theophylline sensitivity Thymus. 1982; 4 (6): 323—34.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">JaffarZ. Н., Sullivan Р., Раде С., Costello J. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur. Respir. J. 1996; 9 (3): 456—62.</mixed-citation><mixed-citation xml:lang="en">JaffarZ. H., Sullivan P., Page C., Costello J. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur. Respir. J. 1996; 9 (3): 456—62.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Montano L. M., Sommer B., Gomez-Verjan J. C. et al. Theophylline: Old Drug in a New Light, Application in COVID-19 through Computational Studies. Int. J. Mol. Sci. 2022; 23 (8): 4167.</mixed-citation><mixed-citation xml:lang="en">Montano L. M., Sommer B., Gomez-Verjan J. C. et al. Theophylline: Old Drug in a New Light, Application in COVID-19 through Computational Studies. Int. J. Mol. Sci. 2022; 23 (8): 4167.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Адамович T Г, Титов Л. П. Продукция IFN-у и IL-4 мононуклеарами периферической крови детей с бронхиальной астмой, получавших рибомунил и комплекс «Теотард» и рибомунил. Проблемы здоровья и экологии. 2007; (4): 17—21.</mixed-citation><mixed-citation xml:lang="en">Adamovich T G., Titov L. P Production of IFN-g and IL-4 by peripheral blood mononuclear cells of children with bronchial asthma treated with ribomunil and the Teotard complex and ribomunil. Problemy zdorov’ya I ekologii. 2007; (4): 17—21. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Sottini A., Serana F, Bertoli D. et al. Simultaneous quantification of T-cell receptor excision circles (TRECs) and К-deleting recombination excision circles (KRECs) by realtime PCR. J Vis Exp. 2014; (94): 52184.</mixed-citation><mixed-citation xml:lang="en">Sottini A., Serana F, Bertoli D. et al. Simultaneous quantification of T-cell receptor excision circles (TRECs) and К-deleting recombination excision circles (KRECs) by realtime PCR. J Vis Exp. 2014; (94): 52184.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Cuvelier P, Roux Н., Couedel-Courteille A. et al. Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome. Crit. Care. 2021; 25 (1): 4.</mixed-citation><mixed-citation xml:lang="en">Cuvelier P., Roux H., Couedel-Courteille A. et al. Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome. Crit. Care. 2021; 25 (1): 4.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Полякова E., Стеганцева M., Гурьянова И. и др. Кольцевые молекулы Т- и В-клеточного рецепторов (TREC/KREC) в дифференциальной диагностике первичных иммунодефицитов. Наука и инновации. 2019; 8 (198): 75—8.</mixed-citation><mixed-citation xml:lang="en">Polyakova E., Stegantseva M., Gur’yanova I. i dr. Circular molecules of T- and B-cell receptors (TREC/KREC) in the differential diagnosis of primary immunodeficiencies. Naukaiinnovatsii. 2019; 8 (198): 75—8. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Васильев Г В., Петрова Т. В., Никифорова А. И. и др. Иммуномодулирующая противоопухолевая терапия как причина ложноположительных результатов неонатального скрининга на первичные иммунодефициты. Иммунология. 2023; 44 (1): 89—92.</mixed-citation><mixed-citation xml:lang="en">Vasil’ev G.V., Petrova T. V., Nikiforova A. I. i dr. Immunomodulatory antitumor therapy as a cause of falsepositive results of neonatal screening for primary immunodeficiencies. Immunologiya. 2023; 44 (1): 89—92. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">De Simone M., Rossetti G., Pagani M. Single cell T cell receptor sequencing: techniques and future challenges. Front. Immunol. 2018; 9: 1638.</mixed-citation><mixed-citation xml:lang="en">De Simone M., Rossetti G., Pagani M. Single cell T cell receptor sequencing: techniques and future challenges. Front. Immunol. 2018; 9: 1638.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Samir A., Bastawi R. A., Baess N. I. et al.Thymus CT-grading and rebound hyperplasia during COVID-19 infection: a CT volumetric study with multivariate linear regression analysis. Egypt. J. Radiol. Nucl. Med. 2022; 53 (1): 112.</mixed-citation><mixed-citation xml:lang="en">Samir A., Bastawi R. A., Baess N. I. et al.Thymus CT-grading and rebound hyperplasia during COVID-19 infection: a CT volumetric study with multivariate linear regression analysis. Egypt. J. Radiol. Nucl. Med. 2022; 53 (1): 112.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Keeton R., Tincho M. B., Ngomti A. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022; 603 (7901): 488—92.</mixed-citation><mixed-citation xml:lang="en">Keeton R., Tincho M. B., Ngomti A. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022; 603 (7901): 488—92.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Matinnez-Gallo M., Esperala J., Pujol-Borrell R. et al. Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. Med. Clin. (Barc). 2022; 159 (3): 116—23.</mixed-citation><mixed-citation xml:lang="en">Matinnez-Gallo M., Esperala J., Pujol-Borrell R. et al. Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. Med. Clin. (Barc). 2022; 159 (3): 116—23.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Лягоскин В., Каргополова П. E., Объедков Д. А. и др. Внутрилабораторная валидация «TиграTестSARS-CoV-2» — теста на высвобождение интерферона гаммa in vitro для определения в крови Т-лимфоцитов, специфически отвечающих на антигены вируса SARS-CoV-2. Инфекция и иммунитет. 2022; 12 (4): 701—13.</mixed-citation><mixed-citation xml:lang="en">Lyagoskin V., Kargopolova P. E., Ob’edkov D. A. i dr. In-laboratory validation of «TigraTest SARS-CoV-2» — an in vitro test for the release of interferon gamma for the determination of T-lymphocytes in the blood that specifically respond to antigens of the SARS-CoV-2 virus. Infektsiya i immunitet. 2022; 12 (4): 701—13. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Bercovici N., Duffour M. T., Agrawal S. et al. New methods for assessing T-cell responses. Clin. Diagn. Lab. Immunol. 2000; 7 (6): 859—64.</mixed-citation><mixed-citation xml:lang="en">Bercovici N., Duffour M. T., Agrawal S. et al. New methods for assessing T-cell responses. Clin. Diagn. Lab. Immunol. 2000; 7 (6): 859—64.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Soares A., Govender L., Hughes J. et al. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods. 2010; 362 (1—2): 43—50.</mixed-citation><mixed-citation xml:lang="en">Soares A., Govender L., Hughes J. et al. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods. 2010; 362 (1—2): 43—50.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Biotechnology company. USA. 2023. Available at: https://www.miltenyibiotec.com</mixed-citation><mixed-citation xml:lang="en">Biotechnology company. USA. 2023. Available at: https://www.miltenyibiotec.com</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Murugesan K., Jagannathan P, Altamirano J. et al. Long-term accuracy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interferon-г release assay and its application in household investigation. Clin. Infect. Dis. 2022; 75 (1): e314—e321.</mixed-citation><mixed-citation xml:lang="en">Murugesan K., Jagannathan P., Altamirano J. et al. Long-term accuracy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interferon-г release assay and its application in household investigation. Clin. Infect. Dis. 2022; 75 (1): e314—e321.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Gallais F., Velay A., Nazon C. et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. Emerg. Infect. Dis. 2021; 27 (1): 113—21.</mixed-citation><mixed-citation xml:lang="en">Gallais F., Velay A., Nazon C. et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. Emerg. Infect. Dis. 2021; 27 (1): 113—21.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Schrotri M., vanSchalwyk M. C. I., Post N. et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2021; 16 (1): e0245532.</mixed-citation><mixed-citation xml:lang="en">Schrotri M., vanSchalwyk M. C. I., Post N. et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2021; 16 (1): e0245532.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Ojeda D. S., Gansales Lopes Ledesma M. M., Pallares O. M. etal. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoSPathog. 2021; 17 (1): e1009161.</mixed-citation><mixed-citation xml:lang="en">Ojeda D. S., Gansales Lopes Ledesma M. M., Pallares O. M. etal. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoSPathog. 2021; 17 (1): e1009161.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Safont G., Lattore I., Villar-Hermandez R. et al. Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management. J. Clin. Med. 2022; 11 (17): 5103.</mixed-citation><mixed-citation xml:lang="en">Safont G., Lattore I., Villar-Hermandez R. et al. Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management. J. Clin. Med. 2022; 11 (17): 5103.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Dan J. M., Mateus J., Kabo Yu. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371 (6529): eabf4063.</mixed-citation><mixed-citation xml:lang="en">Dan J. M., Mateus J., Kabo Yu. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371 (6529): eabf4063.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Wang G., Wang Y., Jiang S. et al. Comprehensive analysis of TCR repertoire of COVID-19 patients in different infected stage. Genes Genomics. 2022; 44 (7): 813—22.</mixed-citation><mixed-citation xml:lang="en">Wang G., Wang Y., Jiang S. et al. Comprehensive analysis of TCR repertoire of COVID-19 patients in different infected stage. Genes Genomics. 2022; 44 (7): 813—22.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Sidney J., Peters B., Sette A. Epitope prediction and identification- adaptive T cell responses in humans. Semin Immunol. 2020; 50: 101418.</mixed-citation><mixed-citation xml:lang="en">Sidney J., Peters B., Sette A. Epitope prediction and identification- adaptive T cell responses in humans. Semin Immunol. 2020; 50: 101418.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
